Clinical Proof of Mechanism for preCISION Platform

Avacta’s AVA6103 shows strong early safety and PK data but efficacy proof is years away.

What the company is saying

Avacta is positioning AVA6103 as a next-generation peptide-drug conjugate with a clean safety profile and controlled-release mechanism, highlighting clinical proof of mechanism in the ongoing Phase 1 FOCUS-01 trial. The company emphasizes that AVA6103 achieved a payload dose 50% higher than the maximum tolerated dose of conventional exatecan with minimal toxicity, and that pharmacokinetic data from patients align closely with preclinical models. CEO Christina Coughlin frames these results as a major inflection point for the platform, underscoring the rapid progression from candidate selection to clinical readout and the potential to address a broad range of solid tumors, citing FAP expression in ~90% of such cancers. The announcement stresses a head-to-head preclinical comparison where AVA6103 outperformed Enhertu® in animal models, using this as a proxy for potential clinical advantage. The tone is confident and forward-looking, with repeated references to ongoing partnership discussions and future data presentations at major oncology conferences. The company is explicit about the next milestones, including further clinical data in H1 2027 and upcoming program updates in Q4 2026.

What the data suggests

The disclosed safety data for AVA6103 are favorable: neutropenia occurred in 0% of patients (versus 22% for Enhertu® and 64% for conventional exatecan at similar doses), thrombocytopenia in 5% (Enhertu® 11%, exatecan 43%), anemia in 16% (Enhertu® 11%, exatecan 43%), and nausea/vomiting in 5% (Enhertu® 44%, exatecan 67%). The first three dose levels—1.5, 3, and 4.5 mg/m2—were completed in 19 patients, with the highest dose representing a 50% increase over the MTD of conventional exatecan. Pharmacokinetic data show AVA6103 is retained and slowly releases exatecan in tumors, with peptide detected in plasma up to 48 hours post-dose, consistent with the intended mechanism. Preclinical efficacy data in a HER2+ FAP+ xenograft model showed all 6 animals treated with AVA6103 had deep and prolonged partial responses, while Enhertu® slowed tumor growth but produced only two minor regressions and one progression. No clinical efficacy data in humans are yet available; the strongest efficacy claims rely on animal studies. The trial is still in Phase 1, with enrollment ongoing and first human efficacy data not expected until H1 2027. No financial, revenue, or operational metrics are disclosed.

Analysis

The announcement is upbeat and highlights meaningful clinical progress, specifically the achievement of clinical proof of mechanism for AVA6103 and a favorable safety profile at higher dose levels. The data disclosed are robust for a Phase 1 trial, with detailed safety and pharmacokinetic metrics and a clear comparison to existing therapies. However, the most significant efficacy claims are still preclinical (animal data), and the first clinical efficacy data are not expected until H1 2027, making the timeline for any commercial or late-stage clinical benefit long-term. The language occasionally overstates the significance of early-stage findings, such as describing preclinical results as 'better antitumor activity' versus a marketed drug, which is not yet demonstrated in humans. There is no mention of large capital outlays or immediate financial impact, and no financial or profitability metrics are disclosed, which is typical for this stage but limits the investment signal. Overall, the narrative is somewhat inflated relative to the actual stage of development, but the technical disclosures are credible and specific.

Risk flags

• ●The absence of human efficacy data means that all claims of superior antitumor activity are based on animal models, which frequently fail to predict clinical outcomes in oncology. This creates a major translational risk between preclinical promise and patient benefit.
• ●The timeline to meaningful clinical readouts is long, with first efficacy data not due until H1 2027. Extended development timelines increase the risk of clinical attrition, shifting competitive landscapes, and potential dilution or funding challenges before commercial validation.
• ●Safety data are limited to the first 19 patients and three dose levels; higher doses or broader patient populations may reveal new toxicities or reduce the apparent safety advantage. Early-phase safety signals often change as trials progress.
• ●The company provides no financial data, cash runway, or funding plan, leaving investors unable to assess whether Avacta can sustain operations through to key clinical milestones. This financial opacity is a material risk for a pre-revenue biotech.
• ●The announcement uses strong language to frame the results as a 'major inflection point' and claims gateway access to previously unaddressable markets, but these are not yet supported by clinical or commercial evidence, raising the risk of overpromising relative to actual progress.

Bottom line

Avacta’s announcement demonstrates that AVA6103 can be dosed at levels 50% above the MTD of conventional exatecan with a markedly improved safety profile in early Phase 1 data, and pharmacokinetic results support the intended tumor-specific release mechanism. However, all efficacy claims are preclinical, and the first human efficacy data will not be available until at least H1 2027, making this a long-term, high-risk proposition. The lack of financial disclosure leaves a critical gap in assessing Avacta’s ability to fund continued development. Investors should focus on future clinical readouts and any evidence of efficacy in humans, as well as updates on funding and partnerships. The most important takeaway is that while the safety and PK data are promising, there is no clinical efficacy signal yet, and the path to value realization is long and uncertain.

Announcement summary

(AIM:AVCT) Avacta Group plc announced that it has achieved clinical proof of mechanism for AVA6103, its next-generation controlled-release pre|CISION® peptide-drug conjugate (PDC) platform, in the ongoing Phase 1 FOCUS-01 trial. Preliminary data from the Phase 1a trial of AVA6103 in patients with select solid tumors demonstrate proof of mechanism with two key findings: AVA6103 pre|CISION® controlled-release exatecan demonstrates a clean safety profile through the first three dose levels, including a payload dose level 50% higher than the maximum tolerated dose (MTD) of conventional exatecan, and the comparison of the preclinical modeled pharmacokinetic (PK) data and clinical trial PK data demonstrates an exceptional alignment through the first 3 dose levels with controlled release of exatecan evident in patients for days after dosing. The first head-to-head comparison of AVA6103 and Enhertu®, a marketed antibody drug conjugate (ADC) that targets HER2, demonstrates that AVA6103 shows better antitumor activity versus Enhertu®, with deep and durable responses delivered by the dose dense regimen applied in the FOCUS-01 trial. Christina Coughlin, Chief Executive Officer of Avacta, stated that the proof of mechanism data with AVA6103 underscores the potential of the platform and that AVA6103 moved from candidate status to Investigational New Drug application in less than a year, now reaching an initial clinical readout with excellent safety and PK data. The FOCUS-01 Phase 1 clinical trial of AVA6103 is enrolling patients with locally advanced or metastatic disease with one of six indications: colorectal cancer, pancreatic ductal adenocarcinoma, gastric/gastroesophageal junction cancers, cervical cancer, or small cell lung cancer. The first three dose levels have completed enrollment of patients (n=19) in two parallel arms with doses administered every two weeks (Q2W) or every three weeks (Q3W) and assessed for safety and tolerability, PK/pharmacodynamics (PD), and preliminary efficacy. The first three dose levels in the AVA6103 trial were 1.5 mg/m2, 3 mg/m2, and 4.5 mg/m2. Dose level 2 of AVA6103 is similar to the MTD of conventional exatecan, and dose level 3 represents an approximate 50% increase over this MTD. Safety data show neutropenia rates of 0% with AVA6103, 22% with similar doses of Enhertu®, and 64% at the MTD of conventional exatecan; thrombocytopenia rates of 5% (1/19) with AVA6103, 11% with Enhertu®, and 43% with conventional exatecan; anemia rates of 16% (3/19) with AVA6103, 11% with Enhertu®, and 43% with conventional exatecan; and nausea and vomiting rates of 5% (1/19) with AVA6103, 44% with Enhertu®, and 67% with exatecan. Pharmacokinetic data show rapid reduction in plasma level of AVA6103 with prolonged low-level release of both products of the cleavage reaction, and detection of low levels of the released peptide from AVA6103 in plasma up to 48 hours after dosing. In a preclinical efficacy comparison, AVA6103 treatment resulted in deep and prolonged partial responses in 6/6 animals, while Enhertu® treatment resulted in slowed growth compared to vehicle control, with two animals demonstrating small tumor reductions and 1/6 with progression as best response. The FOCUS-01 trial continues to enroll patients into two parallel arms at dose level 4. First efficacy data from the FOCUS-01 trial with AVA6103 is anticipated to be presented in H1 2027, and the selection of payloads and data to support clinical candidate selection for the Dual Payload Next Gen Program (AVA6207) will be presented in Q4 2026. Clinical data from the First Gen faridoxorubicin (AVA6000) program will also be presented in Q4 2026 at the ESMO Congress.

Disagree with this article?